Oral L-carnitine and Inflammatory and Nutritional Biomarkers in Maintenance Hemodialysis (NCT07249229) | Clinical Trial Compass
CompletedPhase 2
Oral L-carnitine and Inflammatory and Nutritional Biomarkers in Maintenance Hemodialysis
Iran50 participantsStarted 2020-11-30
Plain-language summary
The goal of this clinical trial is to evaluate whether oral L-carnitine supplementation helps reduce inflammation and improve nutritional status in patients with end-stage kidney disease who are undergoing long-term hemodialysis.
A total of 50 participants will be randomly assigned to receive either:
* Oral L-carnitine solution (1 g, three times per week after dialysis), or
* A placebo solution that looks and tastes the same but does not contain L-carnitine.
The study will last for three months. Researchers will assess changes in:
* Inflammatory markers (high-sensitivity C-reactive protein, hs-CRP)
* Nutritional markers (serum albumin, ferritin)
* Blood lipid profile (cholesterol, LDL, HDL, triglycerides)
The findings from this study are expected to provide insights into the potential clinical benefits of oral L-carnitine supplementation in maintenance hemodialysis patients.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years
* On maintenance hemodialysis for at least 6 months
* Clinically stable for ≥ 3 months
* No hospitalization in the preceding 3 months
* Willingness to provide written informed consent and comply with study procedures
Exclusion Criteria:
* Use of statins, erythropoietin, corticosteroids, NSAIDs, or other anti-inflammatory/lipid-lowering agents within the previous 3 months
* Active infection, inflammatory disease, malignancy, or severe hepatic dysfunction
* Pregnancy or breastfeeding
* Participation in another clinical trial within the preceding 3 months
* Uncontrolled comorbidities (e.g., uncontrolled diabetes or hypertension)
* Acute cardiovascular events within the past 6 months
* Planned kidney transplantation during the study period
* Anticipated poor compliance
* Use of medications that could affect inflammatory or lipid parameters
* History of hypersensitivity to L-carnitine
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.